Why the study?
Does intrathecal methotrexate treat eosinophilic meningitis in a patient with Hodgkin's disease?
Does intrathecal methotrexate treat eosinophilic meningitis in a patient with Hodgkin's disease?
Eosinophilic meningitis is a rare but treatable complication of Hodgkin's disease that can respond to intrathecal methotrexate.
Answers are grounded in this paper and cite their sources.
Suggests intrathecal methotrexate as possible option for eosinophilic meningitis in Hodgkin's disease; leaves open confirmation in prospective studies.
Eosinophilic meningitis is rare in Hodgkin's disease. Five previous cases have been reported. We describe an additional patient whose CSF showed an eosinophilic pleocytosis with Reed-Sternberg cells while in complete systemic remission from Hodgkin's disease. The patient responded to intrathecal administration of methotrexate given by Ommaya reservoir. Six months later, systemic relapse occurred, but the CSF remained normal. Eosinophilic meningitis is a treatable complication of Hodgkin's disease, and prolonged response is possible.
No takes yet. Share an insight, caveat, or question.
Dickerman Hollister (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: